Malaria Vaccine Target: Australian Research Breakthrough
New mRNA Vaccine Blocks Malaria Transmission with 99.7% Efficacy
Table of Contents
Malaria remains one of the world’s most devastating infectious diseases, but a groundbreaking new mRNA vaccine developed by researchers at the Walter and Eliza Hall Institute (WEHI) and the Monash Institute of Pharmaceutical Sciences (MIPS) offers a meaningful leap forward in malaria prevention. The vaccine, targeting a crucial stage in the parasite’s life cycle within the mosquito, has demonstrated up to 99.7% efficacy in blocking malaria transmission in preclinical studies. This innovative approach leverages the power of mRNA technology – proven effective with COVID-19 vaccines – to tackle a persistent global health challenge.
Unlocking a New Vaccine Target Through Structural Biology
For years, a key obstacle in malaria vaccine development has been identifying vulnerable targets within the parasite’s complex life cycle. Researchers focused on Plasmodium falciparum, the most deadly malaria parasite species, and pinpointed a protein complex essential for fertilization within the mosquito – Pfs230 and Pfs48/45.
Using cutting-edge cryo-electron microscopy (cryo-EM), the team determined the precise 3D structure of this complex. This structural discovery was pivotal. Crucially, when the genes responsible for producing these proteins were removed in genetically modified parasites, fertilization failed and transmission was blocked, illuminating a new vaccine target. The research, published in Science, provides a detailed understanding of how these proteins interact, paving the way for targeted vaccine design.
Next-Generation mRNA Vaccine Design and Extraordinary Results
Building on the structural discovery, the team designed a next-generation mRNA vaccine, expertly formulated in collaboration with the mRNA Core facility at MIPS. mRNA vaccines work by delivering genetic instructions to cells, prompting them to produce a harmless piece of the target protein – in this case, components of the Pfs230/Pfs48/45 complex. This triggers an immune response, preparing the body to fight off the real parasite.
In preclinical studies,the vaccine triggered remarkably high levels of antibodies that specifically recognised the parasite. These antibodies effectively blocked transmission in mosquitoes by up to 99.7%, demonstrating the vaccine’s potent ability to interrupt the malaria lifecycle.
Professor Colin Pouton from MIPS highlighted the significance of the collaboration. “It was an exciting possibility for my team to leverage our expertise in mRNA vaccine development to address an crucial new target for malaria vaccination,” he said. ”Drawing on experience through mRNA Core, the MIPS team shifted focus to tackle a new challenge in malaria vaccination. The success of the malaria vaccine program illustrates the versatility of mRNA technology, which has many applications beyond the COVID vaccines.”
He further emphasized the benefits of the collaborative habitat: “It was especially rewarding to work on this project with the WEHI team, co-located in the parkville precinct, where shared expertise has helped drive a new approach to malaria prevention.”
A Vulnerable Stage: Targeting the Parasite in the Mosquito
This vaccine represents a paradigm shift in malaria prevention by targeting the parasite inside the mosquito. This strategy exploits a critical vulnerability known as a “population bottleneck.”
While malaria parasites thrive in the human bloodstream,only a small fraction successfully transition to the sexual stages required for reproduction within the mosquito. Furthermore, triumphant fertilization is a rare event. This bottleneck means that even a modest reduction in parasite numbers at this stage can dramatically reduce overall transmission rates.
Transmission-blocking vaccines, like the one developed hear, offer a strategic advantage by halting the spread of malaria at its weakest point. They don’t prevent infection in humans, but they prevent infected individuals from transmitting the parasite to mosquitoes, ultimately breaking the cycle of disease.
Towards Malaria Elimination: A Multi-Stage Strategy
The researchers envision this mRNA vaccine as a crucial component of a comprehensive, multi-stage malaria elimination strategy. Currently, most malaria vaccine efforts focus on preventing infection in humans by targeting the parasite during the blood or liver stages.
By combining transmission-blocking vaccines with vaccines that protect humans, researchers aim to create a robust, layered defense against malaria. This integrated approach could significantly reduce the overall malaria burden and accelerate progress towards global elimination.
Professor Tham underscored the importance of the collaborative research ecosystem. ”The ability to design, formulate and test vaccine candidates within a single research ecosystem has accelerated the path from discovery to preclinical validation,” she said. “The collaboration between WEHI and MIPS highlighted the strength of the Melbourne Biomedical Precinct and the potential of mRNA technology to rapidly translate basic science into vaccine innovation.”
source:
Walter and Eliza Hall Institute: https://www.wehi.edu.au/
Journal reference:
Dietrich, M. H